Why the study?
The bleeding risk of current antithrombotic strategies in clinical settings, including recently developed agents, needed to be clarified.
What is the incidence of major bleeding in patients with cerebrovascular or cardiovascular diseases taking oral antithrombotic agents in clinical practice?
Population
5306 patients with cerebrovascular or cardiovascular diseases taking oral antiplatelet or anticoagulant agents
Comparison
Oral antiplatelet vs anticoagulant vs combined antithrombotic regimens
Design
Investigator-initiated prospective multicentre observational study
Follow-up
Two years
Authors
Loading...
Higher SVD burden may raise antithrombotic bleeding risk; leaves open whether MRI screening should guide therapy.
What is the incidence of major bleeding in patients with cerebrovascular or cardiovascular diseases taking oral antithrombotic agents in clinical practice?
This prospective observational study will provide real-world data on the incidence of bleeding complications associated with contemporary oral antithrombotic therapies in patients with cardiovascular and cerebrovascular diseases.
Takagi et al. (2020) studied this question.